Login / Signup

Cerebellar α6GABA A Receptors as a Therapeutic Target for Essential Tremor: Proof-of-Concept Study with Ethanol and Pyrazoloquinolinones.

Ya-Hsien HuangMing Tatt LeeHan-Yun HsuehDaniel E KnutsonJames CookMarko D MihovilovicWerner SieghartLih-Chu Chiou
Published in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2023)
Ethanol has been shown to suppress essential tremor (ET) in patients at low-to-moderate doses, but its mechanism(s) of action remain unknown. One of the ET hypotheses attributes the ET tremorgenesis to the over-activated firing of inferior olivary neurons, causing synchronic rhythmic firings of cerebellar Purkinje cells. Purkinje cells, however, also receive excitatory inputs from granule cells where the α6 subunit-containing GABA A receptors (α6GABA A Rs) are abundantly expressed. Since ethanol is a positive allosteric modulator (PAM) of α6GABA A Rs, such action may mediate its anti-tremor effect. Employing the harmaline-induced ET model in male ICR mice, we evaluated the possible anti-tremor effects of ethanol and α6GABA A R-selective pyrazoloquinolinone PAMs. The burrowing activity, an indicator of well-being in rodents, was measured concurrently. Ethanol significantly and dose-dependently attenuated action tremor at non-sedative doses (0.4-2.4 g/kg, i.p.). Propranolol and α6GABA A R-selective pyrazoloquinolinones also significantly suppressed tremor activity. Neither ethanol nor propranolol, but only pyrazoloquinolinones, restored burrowing activity in harmaline-treated mice. Importantly, intra-cerebellar micro-injection of furosemide (an α6GABA A R antagonist) had a trend of blocking the effect of pyrazoloquinolinone Compound 6 or ethanol on harmaline-induced tremor. In addition, the anti-tremor effects of Compound 6 and ethanol were synergistic. These results suggest that low doses of ethanol and α6GABA A R-selective PAMs can attenuate action tremor, at least partially by modulating cerebellar α6GABA A Rs. Thus, α6GABA A Rs are potential therapeutic targets for ET, and α6GABA A R-selective PAMs may be a potential mono- or add-on therapy.
Keyphrases